Levosulpiride and racemic sulpiride in non-ulcer dyspepsia: Results of a randomized clinical study

T. Tosi, E. Masci, D. Ceppodomo, P. A. Testoni

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Using racemic sulpiride as a reference drug, we assessed the usefulness of levosulpiride (the levo-isomer of sulpiride) in the management of non-ulcer dyspepsia. In this double-blind, randomized study, 50 patients with non-ulcer dyspepsia received 25 mg of levosulpiride or 50 mg of racemic sulpiride three times daily for 30 days. Symptomatic improvement was evaluated by interview at the end of the study. Globally, a good or excellent result was obtained in both groups (P <0.01) with no statistical difference. Levosulpiride markedly reduced the severity of anorexia, nausea, postprandial fullness, belching, and epigastric pain without significant side effects. The results suggest that levosulpiride, at 25 mg TID, is effective in the treatment of chronic functional dyspepsia.

Original languageEnglish
Pages (from-to)787-791
Number of pages5
JournalCurrent Therapeutic Research
Volume51
Issue number6
Publication statusPublished - 1992

Fingerprint

Sulpiride
Dyspepsia
Eructation
Anorexia
Double-Blind Method
Nausea
levosulpiride
Clinical Studies
Interviews
Pain
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Levosulpiride and racemic sulpiride in non-ulcer dyspepsia : Results of a randomized clinical study. / Tosi, T.; Masci, E.; Ceppodomo, D.; Testoni, P. A.

In: Current Therapeutic Research, Vol. 51, No. 6, 1992, p. 787-791.

Research output: Contribution to journalArticle

@article{3a9d35f454a54ce480ef8631fdff9a97,
title = "Levosulpiride and racemic sulpiride in non-ulcer dyspepsia: Results of a randomized clinical study",
abstract = "Using racemic sulpiride as a reference drug, we assessed the usefulness of levosulpiride (the levo-isomer of sulpiride) in the management of non-ulcer dyspepsia. In this double-blind, randomized study, 50 patients with non-ulcer dyspepsia received 25 mg of levosulpiride or 50 mg of racemic sulpiride three times daily for 30 days. Symptomatic improvement was evaluated by interview at the end of the study. Globally, a good or excellent result was obtained in both groups (P <0.01) with no statistical difference. Levosulpiride markedly reduced the severity of anorexia, nausea, postprandial fullness, belching, and epigastric pain without significant side effects. The results suggest that levosulpiride, at 25 mg TID, is effective in the treatment of chronic functional dyspepsia.",
author = "T. Tosi and E. Masci and D. Ceppodomo and Testoni, {P. A.}",
year = "1992",
language = "English",
volume = "51",
pages = "787--791",
journal = "Current Therapeutic Research - Clinical and Experimental",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "6",

}

TY - JOUR

T1 - Levosulpiride and racemic sulpiride in non-ulcer dyspepsia

T2 - Results of a randomized clinical study

AU - Tosi, T.

AU - Masci, E.

AU - Ceppodomo, D.

AU - Testoni, P. A.

PY - 1992

Y1 - 1992

N2 - Using racemic sulpiride as a reference drug, we assessed the usefulness of levosulpiride (the levo-isomer of sulpiride) in the management of non-ulcer dyspepsia. In this double-blind, randomized study, 50 patients with non-ulcer dyspepsia received 25 mg of levosulpiride or 50 mg of racemic sulpiride three times daily for 30 days. Symptomatic improvement was evaluated by interview at the end of the study. Globally, a good or excellent result was obtained in both groups (P <0.01) with no statistical difference. Levosulpiride markedly reduced the severity of anorexia, nausea, postprandial fullness, belching, and epigastric pain without significant side effects. The results suggest that levosulpiride, at 25 mg TID, is effective in the treatment of chronic functional dyspepsia.

AB - Using racemic sulpiride as a reference drug, we assessed the usefulness of levosulpiride (the levo-isomer of sulpiride) in the management of non-ulcer dyspepsia. In this double-blind, randomized study, 50 patients with non-ulcer dyspepsia received 25 mg of levosulpiride or 50 mg of racemic sulpiride three times daily for 30 days. Symptomatic improvement was evaluated by interview at the end of the study. Globally, a good or excellent result was obtained in both groups (P <0.01) with no statistical difference. Levosulpiride markedly reduced the severity of anorexia, nausea, postprandial fullness, belching, and epigastric pain without significant side effects. The results suggest that levosulpiride, at 25 mg TID, is effective in the treatment of chronic functional dyspepsia.

UR - http://www.scopus.com/inward/record.url?scp=0026764179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026764179&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0026764179

VL - 51

SP - 787

EP - 791

JO - Current Therapeutic Research - Clinical and Experimental

JF - Current Therapeutic Research - Clinical and Experimental

SN - 0011-393X

IS - 6

ER -